Cytek Biosciences, Inc. — Form 8-K Summary
Business Context and Reporting Period
Cytek Biosciences, Inc. filed this Form 8-K regarding its 2024 annual meeting of stockholders held on June 5, 2024. The filing reports voting results under Item 5.07. The report was signed on June 11, 2024.
Key Financial Metrics
This filing does not provide current-period revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics. It references approval of executive compensation for the year ended December 31, 2023 but provides no compensation amounts.
Material Governance Results
- Of 131,264,277 shares outstanding as of the April 8, 2024 record date, 97,102,801 shares were represented at the meeting, or approximately 74%.
- Class III directors elected: Wenbin Jiang, Ph.D. received 64,177,338 votes for, 9,915,036 withheld, and 23,010,427 broker non-votes. Michael Holder received 70,298,785 votes for, 3,793,589 withheld, and 23,010,427 broker non-votes. Both will serve until the 2027 annual meeting, subject to earlier termination.
- Executive compensation: Advisory approval was received for 2023 named executive officer compensation, with 63,537,386 votes for, 10,476,039 against, 78,949 abstentions, and 23,010,427 broker non-votes.
- Independent auditor: Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The vote was 94,116,564 for, 2,329,549 against, and 656,688 abstentions, with no broker non-votes.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance, operational outlook, material risk updates, contingencies, or unusual financial items. The principal reported developments are the election of two directors, advisory approval of executive compensation, and auditor ratification.
Investor Verification Items
- Confirm the elected directors’ committee assignments, tenure, and any related governance changes in subsequent filings.
- Review the company’s proxy statement for detailed executive compensation, incentive arrangements, and shareholder voting recommendations.
- Monitor subsequent filings for auditor-related disclosures, financial results, liquidity information, and management outlook not included in this 8-K.